

Biocon Biologics Inc. 685 Route 202 Suite # 204 Bridgewater, NJ 08807

November 12, 2025

Notice Regarding Adjustment of 340B Prices for Select Products of Biocon Biologics Inc.

Biocon Biologics Inc., ('Biocon') has recalculated its 340B ceiling prices of the products and corresponding national drug codes ("NDCs") referenced below for the sales period commencing April 1, 2024 through June 30, 2025 (the "Restatement Period"), due to revisions made to Biocon's Medicaid pricing data.

As a result of the recalculated 340B Ceiling Prices, Biocon has determined the credit amount owed to each affected Covered Entity. Biocon has asked the Office of Pharmacy Affairs ("OPA") within HRSA to post this Notice on the public website to ensure transparency by providing access to information about the recalculation affecting certain 340B Covered Entities for the impacted product(s).

Biocon will work through Apexus, the HRSA 340B Prime Vendor, to issue refunds to each affected Covered Entity. Refunds will be issued either to a Covered Entity's validated wholesaler pharmacy account when one can be identified, or an ACH or check will be issued to Covered Entities whose wholesaler account cannot be identified.

The table below identifies the NDCs, products, and sales periods that are subject to a refund.

| NDC | Product Description | Sales Period |
|-------------|--|-------------------|
| 49502039380 | Insulin Glargine Inj 100mL Multi Dose VL | Q2 2024 |
| 49502039475 | Insulin Glargine Inj 100mL/3mL PF Pen | Q2 2024 |
| 83257001411 | INSULIN GLARGINE 10ML VIAL (US 351K) | Q2 2024 |
| 83257001532 | INSULIN GLARGINE PEN (US 351K) | Q2 2024 |
| 49502025080 | SEMGLEE Glargine Inj 100mL Multi Dose VL | Q2 2024 |
| 49502025175 | SEMGLEE Glargine Inj 100 mL/3mL PF Pen | Q2 2024 |
| 83257001233 | SEMGLEE INSULIN GLARGINE Pen US 351K | Q2 2024 |
| 83257000111 | Ogivri for Inj 150 mg Single Dose Vial | Q4 2024 – Q2 2025 |
| 67457099115 | Ogivri for Inj 150 mg Single Dose Vial | Q4 2024 – Q2 2025 |
| 83257000412 | Ogivri for Inj 420mg Multi Dose Vial | Q4 2024 – Q2 2025 |

Biocon has established a refund threshold of \$25 for every product and Restatement Period. Covered Entities that are owed a refund of \$25 or greater will be contacted directly by Apexus with information on how the refund will be processed.

Apexus will not contact Covered Entities that are owed a refund of less than \$25. Any Covered Entity that believes it is either entitled to a refund but has not been contacted by Apexus, or it is owed a refund of less than \$25 should contact Biocon at 340Brefunds@biocon.com to request a refund. The email should include the product, NDC number, quantities purchased, Wholesaler, Wholesaler Invoice Number, Wholesaler Invoice Date, and the applicable 340B IDs for all impacted products.